Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Funding supports trial of TT-P34 as potential treatment

Teitur Trophics has raised €28 million (about $29.7 million) to advance its lead candidate, TT-P34, into a Phase 1b clinical trial as a possible treatment for Parkinson’s and other neurodegenerative diseases. “There is a pressing need for new therapies for neurodegenerative diseases which have a detrimental impact on…

Parkinson’s, specific cancers share genetic risk factors: Study

Researchers have found a genetic association between Parkinson’s disease and melanoma, a type of skin cancer, and prostate cancer. Data also showed that Parkinson’s genetic risk factors are linked to an increased risk of breast cancer and lower risk of ovarian cancer. “Our results suggest the importance of shared genetic…

Inbrija, inhaled levodopa for patients’ off episodes, arrives in Spain

Inbrija (levodopa inhalation powder), an approved therapy for off episodes in Parkinson’s patients on certain standard levodopa-based treatments, is now available in Spain. Developed by Acorda Therapeutics, the therapy was approved in the U.S. in 2018 and for the European Union in 2019. In Spain and Germany — where…

How Parkinson’s May Affect Sexes Differently Examined in US Study

Men with mild-to-moderate Parkinson’s disease may experience greater effects of the disease on certain aspects of their life than women, according to a study of patients living in the southeastern U.S. Specifically, men were found to have worse motor symptoms, daily life-related impairments, disease-related quality of life, and more…

Online Educational Series for Healthcare Professionals Begins

The Parkinson’s Foundation has launched a new education series for healthcare professionals to improve the treatment and health outcomes of people with Parkinson’s disease. The Education Series for Community Providers, developed in collaboration with the CVS Health Foundation, seeks to expand patients’ access to high quality healthcare…

Virtual Reality System May Help Diagnose Parkinson’s

DiagnaMed Holdings will develop a virtual reality and artificial intelligence tool (VR/AI Neuro) for the diagnosis of neurodegenerative diseases, such as Parkinson’s disease. The company acquired an exclusive worldwide license of intellectual property from the KU Center for Technology Commercialization, at the University of Kansas, for the…

Suppressing Enzyme Synuclein Nitrase Could Lead to New Therapies

Nitrase Therapeutics showed suppressing the activity of an enzyme called synuclein nitrase reduces toxic clumps of the alpha-synuclein protein and normalizes the electrical activity of dopamine-producing, or dopaminergic, neurons derived from Parkinson’s patients. The accumulation of toxic alpha-synuclein clumps is the underlying cause of the progressive death of…